Clinical Trial Update: NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for NA-831 (atazanavir and dexamethasone) in COVID-19 infection; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019
• Respiratory Infection
• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• ATAZANAVIR (atazanavir)
• DEXAMETHASONE (Dexamethasone)
• NA-831

Snippet

Sponsor: Biomed Industries, Inc. | Conditions: Coronavirus Infection, Severe Acute Respiratory Infection | Phase 2, Phase 3 | Status: UNKNOWN